US Patent

US12201555 — Drug eluting ocular implant

Composition of Matter · Assigned to Dose Medical Corp · Expires 2031-02-14 · 5y remaining

Vulnerability score 23/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a drug eluting ocular implant capable of controlled release of one or more drugs for treating ocular disorders.

USPTO Abstract

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Drugs covered by this patent

Patent Metadata

Patent number
US12201555
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-02-14
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Dose Medical Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.